Replies to post #210665 on Biotech Values

[DewDiligence]

OCRX presents additional post-hoc data from STOP-HE trial—reports 1Q17 results:

http://ir.ocerainc.com/releasedetail.cfm?releaseid=1025649

I think OCRX has a fair—but not great—chance of persuading the FDA to endorse advancing OCR-002 to phase-3, using the kind of trial design proposed on today's CC.